VXRT Vaxart, Inc. Insider Trading

Director Watson W. Mark buys 20,000 VXRT shares at $0.41 (2 transactions, $8,185 total)

Watson W. Mark, a director, executed 2 separate purchases totaling 20,000 shares at $0.41 per share on 2025-11-17, increasing his holdings by 19.2% to 124,125 shares. The current stock price of $0.36 is below the transaction price and stands 61.7% below the 52-week high of $0.94. Vaxart is unprofitable with net income of $-8,141,000.00 in the latest period, though it posted strong annual revenue growth of +288.9%; however, such growth in a pre-profit biotech context requires scrutiny. At this ticker, Mark's prior buy on 2025-07-29 showed a 90-day return of -11.4%, while his 2024-06-18 purchase returned +38.4% over 90 days—a 50% hit rate on timing—suggesting mixed predictive value from this insider's historical buys at this company.

Director Heron purchases 40,000 shares of VXRT at blended $0.40 avg, raising stake 70.7% to 96.6K shares

Director Elaine J Heron purchased 40,000 shares across 2 transactions on 2025-11-17 at a blended average price of $0.40 per share, materially expanding her position from 56,566 shares to 96.6K shares. The stock currently trades at $0.36, down 61.7% from its 52-week high of $0.94, placing this purchase at a depressed valuation relative to recent trading range. Vaxart remains unprofitable (full-year net income was negative) despite exceptional revenue growth of +288.9% year-over-year, creating a paradoxical fundamental picture that complicates interpretation of the director's motivation. The absence of prior track record data for this insider prevents assessment of historical execution accuracy at this ticker.

Director Finney Kevin purchases 166,668 shares across 6 transactions (Jul-Aug 2025) at blended $0.37, tripling stake to 204,771 shares

Director Kevin Finney executed 6 separate purchases totaling 166,668 shares for $61,933.84 over a five-week period, with prices ranging from $0.35 to $0.40. This action increased his holdings by 437.4%, from 38,103 shares to 204,771 shares. Vaxart is unprofitable (−$15.0M net income in latest full fiscal year) despite strong revenue growth of +288.9% year-over-year, and the stock trades at −62.6% from its 52-week high. The sustained accumulation at price points between $0.35 and $0.40 as the stock declined 16.0% over 30 days and 19.1% over 90 days demonstrates a director building a material position despite operational losses and downward price momentum. Investors should examine Vaxart's path to profitability and the catalyst (if any) that prompted this director-level capital deployment during a period of negative returns.

Director Watson W. Mark bought 10,000 shares of VXRT at $0.40; stock now $0.37, down 19.5% in 30 days as company burns cash with $15.6M net loss despite 288.9% revenue growth.

Director Watson W. Mark purchased 10,000 shares at $0.40 on 2025-07-29, increasing his holdings from 94,125 to 104,125 shares, while Vaxart is unprofitable with a net loss of $15.6M against quarterly revenue of $20.9M. The stock has declined 19.5% over the past 30 days and currently trades at $0.37, down 62.6% from its 52-week high of $0.99. In his cross-ticker track record, Mark's prior buy resulted in a 90-day return of +38.4%, but this does not necessarily predict outcomes at VXRT—his only prior trade at this ticker on 2024-06-18 (also a buy) did achieve a 90-day return of +38.4%, though that represents a single historical data point. The purchase occurs in the context of significant cash burn (quarterly loss exceeding quarterly revenue), which remains the critical operational constraint investors should monitor.

VXRT CEO Lo Steven bought 100,000 shares at $0.49; stock down 51.0% from 52-week high despite +288.9% revenue growth

CEO Lo Steven purchased 100,000 shares at $0.49 on 2025-05-19, establishing his first position in the company. The purchase occurs at a price 51.0% below the 52-week high of $1.02, following a 30-day rally of +45.4% and a 90-day decline of -31.5%. Vaxart's fundamentals show exceptional revenue growth of +288.9% year-over-year to $20.9M in the latest quarter, yet the company reported a net loss of $-15.6M and remains unprofitable on a full-year basis. The CEO's initial buy at a depressed valuation contrasts sharply with the company's explosive top-line expansion, presenting a critical signal about insider perspective on risk-reward despite ongoing operating losses and cash burn.

Director Watson W. Mark purchased 20,000 shares of VXRT at $0.68 on 2024-06-18, raising holdings to 78,125 shares (+34.4%).

Watson W. Mark, a director at Vaxart, purchased 20,000 shares at $0.68 on 2024-06-18, increasing his holdings by 34.4% from 58,125 to 78,125 shares. The purchase occurred amid significant headwinds: the stock has declined 48.9% from its 52-week high of $1.41, fallen 16.3% over the prior 30 days, and dropped 42.9% over the prior 90 days. The company's fundamentals show a net income loss of $-24,417,000.00 in its latest full fiscal year, though quarterly revenue of $2,181,000.00 reflects 6796.3% annual revenue growth. The substantial percentage increase in the director's personal holding stake, paired with a material decline in share price and the company's unprofitable position, warrants investor scrutiny into the director's basis for the acquisition and the company's path to profitability.